Bumetanide

Generic Name: Bumetanide

Brand Names: Bumex, Burinex

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₂O_₅S

CAS Number: 28395-03-1

Unique Ingredient Identifier: 0Y2S3XUQ5H

Background: Bumetanide is a sulfamyl diuretic.

Indication: For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.

Associated Conditions: Edema

Associated Therapies: -

Clinical Trials

Bumetanide in Hypokalaemic Periodic Paralysis

Phase 2

Terminated

Conditions: Hypokalemic Periodic Paralysis

First Posted Date: 2015-10-21

Last Posted Date: 2018-02-07

Lead Sponsor: University College, London

Target Recruit Count: 12

Registration Number: NCT02582476

Locations: 🇬🇧
MRC Centre for Neuromuscular Disorders, London, United Kingdom

NEMO1:NEonatal Seizure Using Medication Off-patent

Phase 1

Completed

Conditions: Neonatal Seizures

Interventions: Drug: Bumetanide

First Posted Date: 2011-09-14

Last Posted Date: 2015-09-14

Lead Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust

Target Recruit Count: 14

Registration Number: NCT01434225

Locations: 🇮🇪
Cork University Maternity Hospital, Cork, Ireland
🇳🇱
Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands

and more 4 locations

Efficiency of Bumetanide in Autistic Children

Phase 3

Completed

Conditions: Autistics Children

Interventions: Drug: bumetanide

First Posted Date: 2010-03-02

Last Posted Date: 2011-12-21

Lead Sponsor: University Hospital, Brest

Target Recruit Count: 60

Registration Number: NCT01078714

Locations: 🇫🇷
DUPIN, Vannes, France
🇫🇷
Lemonnier, Brest, France
🇫🇷
Chevreuil, Rennes, France

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Bumetanide
Drug: Dapagliflozin

First Posted Date: 2009-07-02

Last Posted Date: 2016-10-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 42

Registration Number: NCT00930865

Locations: 🇺🇸
Ppd Development, Lp, Austin, Texas, United States

Pilot Study of Bumetanide for Newborn Seizures

Phase 1

Completed

Conditions: Seizures

Interventions: Drug: Normal Saline as Placebo
Drug: Bumetanide

First Posted Date: 2009-01-28

Last Posted Date: 2020-12-17

Lead Sponsor: Soul, Janet , M.D.

Target Recruit Count: 43

Registration Number: NCT00830531

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Tufts Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 1 locations

Bumetanide Versus Furosemide in Heart Failure

Phase 3

Withdrawn

Conditions: Heart Failure

Interventions: Drug: furosemide
Drug: bumetanide

First Posted Date: 2006-09-07

Last Posted Date: 2014-03-27

Lead Sponsor: Lawson Health Research Institute

Registration Number: NCT00372762

Locations: 🇨🇦
University Hospital, London Health Sciences Centre, London, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy